Non-pharmaceutical interventions (NPI) are public health measures that aim to prevent and/or control SARS-CoV-2 transmission in the community. As long as there is no effective and safe vaccine to protect those at risk of severe COVID-19, NPI are the most effective public health interventions against... COVID-19. These ECDC guidelines detail available options for NPI in various epidemiologic scenarios, assess the evidence for their effectiveness and address implementation issues, including potential barriers and facilitators.
more
This document serves to provide interim guidance/ recommendations to carry out mpox surveillance activities mainly case investigation, contact tracing and isolation. For the development of this document WHO, UKHSA and CDC guidelines were referred to and adopted within the country context.
Submission by the WHO Collaborating Centre on training and policy on opioid availability and WHO collaborating Centre for community participation in palliative care and long term care To the Indian Nursing Council for consideration to be included in the Undergraduate Nursing education curriculum
The Tripartite AMR Country Self-Assessment Survey (TrACSS) helps to monitor country progress on the implementation of AMR national actions plans and has been administered on an annual basis by the Tripartite organizations (Food and Agriculture Organization of the United Nations (FAO), World Organisa...tion for Animal Health (OIE) and World Health Organization (WHO)) since 2016.
This report analyzes the global responses on the fourth round of TrACSS (2019-2020) and examines the global trends and actions towards addressing AMR in all sectors.
Complete country and global responses to all rounds of the survey can be accessed through the TrACSS database: https://amrcountryprogress.org/.
more
The dashboard is based on assessments made by the International Preparedness Strengthening missions to 14 priority countries against each of the activities outlined in the WHO EVD Checklist at the time of each mission. Updates indicating progress against each of the indicators will be added on an o...ngoing basis.
more
Shielding is a term used to describe the protection of individuals at high risk of severe COVID-19 illness by separating them from the general population.
Known avoidable environmental risks to health cause at least 12.6 million deaths every year, and account for about one quarter of the global burden of disease (2016 data) (1). Air pollution alone causes about 7 million
deaths a year, placing it among the top global risks to health (2). Global envir...onmental challenges are on the rise, including climate change, rapid urbanization and increased resistance to drugs.
more
This section deals with implementing and improving infection control practices in hospitals, health centres and other health services in the outbreak area. It explains the need for, and implementation of, effective triage procedures, and basic requirements for infection control and supporting activi...ties. Further guidance can be found in the MSF Infection Control Guideline
more
The summary of the infection prevention and control (IPC) measures is for anyone providing direct and non-direct care to patients with suspected or confirmed Ebola virus disease (EVD) in health-care facilities (HCFs). Essential IPC measures are also included in the Table which can be used as a stand...-alone tool.
more
https://doi.org/10.1016/j.vaccine.2019.09.099
The article "Economic burden of cholera in Asia" examines the financial impact of cholera in 14 Asian countries. It analyzes costs related to treatment, out-of-pocket expenses, and lost productivity due to illness and premature deaths. The study estimat...es that cholera caused approximately $41 million in direct costs and $946 million in lost productivity in 2015. It highlights the significant economic burden on public health systems and households, emphasizing the need for investments in cholera prevention, including improved sanitation, clean water access, and vaccination programs.
more
The International Journal of Tuberculosis and Lung Disease 21(5) DOI: 10.5588/ijtld.16.0518